Privia Health Group, Inc. (PRVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRVA Stock Price Chart Interactive Chart >
PRVA Price/Volume Stats
Current price | $23.81 | 52-week high | $50.77 |
Prev. close | $23.64 | 52-week low | $17.99 |
Day low | $23.40 | Volume | 329,258 |
Day high | $24.30 | Avg. volume | 691,870 |
50-day MA | $24.73 | Dividend yield | N/A |
200-day MA | $25.17 | Market Cap | 2.59B |
Privia Health Group, Inc. (PRVA) Company Bio
Privia Health Group, Inc. operates as a physician practice management and population health technology company in the United States. The company comprises regional medical groups, accountable care organizations, and specialty verticals. It offers technology and population health tools to enhance independent providers' workflows; management service organization that enables providers to reduce administrative work focus on their patients; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; physician-led accountable care organization, which engages patients, reduces inappropriate utilization, and enhances coordination and patient quality metrics to drive value-based care and transform the healthcare delivery system; and network for purchasers and payers. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. operates as a subsidiary of Brighton Health Group Holdings, LLC.
Latest PRVA News From Around the Web
Below are the latest news stories about Privia Health Group Inc that investors may wish to consider to help them evaluate PRVA as an investment opportunity.
Privia Health to Participate in SVB Leerink Virtual Healthcare ConferenceARLINGTON, Va., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that the Company’s management team will participate in a virtual fireside chat as part of the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022, beginning at 4:20 pm ET. The webcast and replay of the event, as well as the accompanying slide presentation, will be available at ir.priviahealth.com/news-and-events/events-and-presentations. About Privia Health Privia |
Privia and Javara collaborate in Moderna’s vaccine study for respiratory syncytial virusPrivia Health Group < |
Javara Contributes to RSV Prevention Vaccine Trial in Collaboration with Privia Health and ModernaJavara, a leading Integrated Research Organization focused on delivering access to clinical trials at the point of care, today announced an opportunity for adults age 60 or older who live in the Fayetteville, Georgia; Annapolis, Maryland; or Fort Worth, Texas areas to participate in a clinical trial of a new investigational vaccine aimed at protecting them from the respiratory syncytial virus (RSV). This clinical trial is being launched in partnership with certain Privia Health Group (Nasdaq: PR |
An Intrinsic Calculation For Privia Health Group, Inc. (NASDAQ:PRVA) Suggests It's 50% UndervaluedIn this article we are going to estimate the intrinsic value of Privia Health Group, Inc. ( NASDAQ:PRVA ) by taking the... |
Privia Health Group: Not Healthy YetNo summary available. |
PRVA Price Returns
1-mo | -2.06% |
3-mo | -6.19% |
6-mo | 0.42% |
1-year | -28.07% |
3-year | N/A |
5-year | N/A |
YTD | -7.96% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
2018 | N/A |
2017 | N/A |
Loading social stream, please wait...